Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis executes option for oral salmon calcitonin

Feb. 18, 2000

Phase III study of ALX1-11 now under way for treatment of osteoporosis

Feb. 17, 2000

Ligand and Organon sign research agreement for progesterone receptor-modulating agents

Feb. 16, 2000

New GRF analogue from Theratechnologies shows promising phase Ib trial results

Feb. 16, 2000

Hemopure significantly eliminates need for blood transfusion in vascular surgery

Feb. 16, 2000

Estrogen/progestin HRT may increase risk of breast cancer, according to NCI study

Feb. 16, 2000

Clinical testing continues with Snow Brand's erythropoietin

Feb. 15, 2000

Plan B receives Canadian approval for postcoital contraception

Feb. 15, 2000

HSL disruption produces sterility without obesity

Feb. 15, 2000

FDA approves Actimmune for treatment of osteopetrosis

Feb. 14, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...